scout
News|Videos|June 18, 2024

Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia and the T315I Mutation: 4-Year Results From OPTIC

Jorge Cortes, MD, discusses 4-year outcomes with ponatinib in patients with chronic myeloid leukemia harboring a T315I mutation.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME